Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea
about
Symptom management and self-care for peripheral neuropathy in HIV/AIDSBarriers to HIV Cure.The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology.Neurologic presentations of AIDS.Neurological and psychiatric adverse effects of antiretroviral drugs.Mitochondrial toxicity and HIV therapy.Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors.Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms.Zidovudine as modern day salvage therapy for HIV infection.Peripheral neuropathy during stavudine-didanosine antiretroviral therapy.Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapyOral and dental care and treatment protocols for the management of HIV-infected patients.Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings.Burning feet in polycythemia vera - peripheral sensorimotor axonal neuropathy with erythromelalgia.Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy.The power of simplicity.The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.Genome-wide screen identifies drug-induced regulation of the gene giant axonal neuropathy (Gan) in a mouse model of antiretroviral-induced painful peripheral neuropathyHIV-associated sensory neuropathy in HIV-1 infected patients at the Douala General Hospital in Cameroon: a cross-sectional study.Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trialAdverse effects of highly active antiretroviral therapy in developing countries.Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathyL-acetylcarnitine: a proposed therapeutic agent for painful peripheral neuropathiesPharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathySecond assessment of NeuroAIDS in AfricaContinued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs.Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity.A meta-analysis of HIV and heart rate variability in the era of antiretroviral therapy.A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.HIV Distal Neuropathic Pain Is Associated with Smaller Ventral Posterior Cingulate Cortex.Influence of Age and Neurotoxic HAART Use on Frequency of HIV Sensory Neuropathy.Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study.Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.Unhealthy behaviours for self-management of HIV-related peripheral neuropathy.Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
P2860
Q22248037-8671FE9B-9EC4-41F0-AE41-14C434BBA739Q30245414-1431F733-BE3C-4ED0-BFC8-B8EF70BAA4ECQ33340463-C748FD99-9CD7-4AB0-B9EE-85D14B712BCBQ33590337-21C4E87E-B7C6-4159-80D0-34B81CA520C4Q34039419-DADA56A8-69CA-4D7A-B850-CA98F6F9E34CQ34279271-C36B8143-B665-43A6-AEDF-DA4959539F42Q34282667-C6C03083-CE6D-49C5-98D5-92967DAEAA30Q34283144-FB0A7360-083A-4C54-92F0-4271450B0FDCQ34436988-0E83AF2A-C43B-48AA-9768-F58D604C0ED7Q34519789-59123762-F26E-4014-85A2-A58B72C749C8Q34612023-C7328B70-A1E9-4755-AA5C-27A0C6BE193BQ34775223-5E1A740B-12DC-4C1D-99A6-58C6C338EF88Q34840325-3DDBA78F-DB55-40D7-9166-3D45D98F316DQ35063492-83BA270E-AEFE-4504-BA44-86988C57C03CQ35217892-DB3CAD4A-0E4F-40CF-882F-26A71984E011Q35583698-F6AC4BCE-3FCA-4DB1-B2CB-7269AE77B1BBQ35676408-BDE508B8-66B1-4826-B4F2-6EFB722B9AA7Q36081993-4D60C8B2-5E1B-4599-8E17-31B81A8771A1Q36441623-4C0B5E16-B8DB-41AB-9875-FD4200A8B39EQ36478702-006E1E90-4CCD-4B81-8A34-066F6AFA8AE8Q36627942-0EBEFE21-9B5E-4877-AB59-2F90B842311EQ36945761-AB9786B3-2730-4949-BB88-C8BC1AB3D75CQ37019423-7C50067E-854F-4104-BA28-C79462CB9907Q37211777-281DC6C4-6DB2-45D7-AA05-621CC0A78DDDQ37251569-8A47A873-F028-45D3-A2BD-5F71474D4216Q37371300-D47450F6-150D-4D8D-9B3C-C834774E2F98Q37584886-F8657CAF-B2CE-45B1-8028-9993452770DDQ37608857-66BF1C32-E692-4512-9754-5B7642EC7B76Q37634512-3C33B97A-9005-45BB-AB85-C3404D8EEE4CQ38891149-8C0D61AE-58F5-434F-8FCA-B8ECA35E9AD2Q39336227-5BC16A07-D04D-4B44-8272-5EDF2C0260FFQ41912825-A28245D3-D01F-4A47-8C01-46FEAA33EA64Q42047014-1F6D4213-7918-4BCC-9AC2-8FAA2EFA3D7AQ42107726-DAA94D64-8A91-4680-926E-592109164312Q42246328-0DDDDA56-783D-44DE-9157-A429AD7CF309Q43787821-E612E68C-2477-4786-83CC-7C1856A45B2EQ44391392-6C58EAF0-D778-41A9-9D0A-767F1D3B4327Q44612861-82F53E7F-AD7B-4F0F-8D46-DC5745A23047Q44650997-12AF5E1E-9BD7-4985-BB56-5930C4153B0EQ44662445-335FBA52-20CB-4A98-9A82-51FB18251D2E
P2860
Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@ast
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@en
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@nl
type
label
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@ast
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@en
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@nl
prefLabel
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@ast
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@en
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@nl
P2093
P1433
P1476
Incidence of neuropathy in HIV ...... ine, stavudine and hydroxyurea
@en
P2093
J C Keruly
J C McArthur
P356
10.1097/00002030-200002180-00009
P407
P577
2000-02-18T00:00:00Z